Atlas Venture Opportunity Fund II, L.P. has filed a Form 144, indicating its intention to sell securities associated with Disc Medicine, Inc. This filing is significant as it reflects the fund's ongoing investment strategy and its engagement in the pharmaceutical sector.
Background
Atlas Venture Opportunity Fund II, L.P. is a limited partnership based in Watertown, Massachusetts. The entity is categorized under the SIC code for pharmaceutical preparations. Recent filings include multiple Form 144 submissions, with the latest dated October 21, 2026, indicating a consistent pattern of securities transactions.
What the Filing Says
The filing states, "Report of proposed sale of securities," which indicates that the fund is preparing to sell its holdings in Disc Medicine, Inc. This move is part of a broader strategy to manage its investment portfolio.
Impact
This filing could affect various stakeholders, including investors in both Atlas Venture Opportunity Fund II and Disc Medicine, Inc. The pharmaceutical preparations sector may also see implications as other firms observe these developments and adjust their strategies accordingly.
What's Next
The filing does not say what happens next.
Details of the Filing
The Form 144 filing was accepted on October 21, 2026, at 17:12:05, indicating a timely submission in accordance with SEC regulations. The filing includes two documents, one of which is a primary document in XML format, while the other is an exhibit labeled EX-99, which is a PDF document.
Company Information
Disc Medicine, Inc., the subject of the securities sale, is identified by its Central Index Key (CIK) number 0001816736. The company operates under the SIC code 2834, which pertains to pharmaceutical preparations. It has a fiscal year end of December 31, 2023.
Contact Information
Atlas Venture Opportunity Fund II, L.P. is located at 321 Arsenal Street, Suite 101, Watertown, MA 02472, with a contact phone number of (617) 674-9274. In contrast, Disc Medicine, Inc. is based at 300 Technology Square, 8th Floor, Cambridge, MA 02139, with a phone number of 857-201-2700.
Absence of Future Plans
The filing does not provide any information regarding future plans or intentions following the proposed sale of securities, leaving stakeholders without insights into the fund's next steps or strategic adjustments.